Glaukos GKOS Rallies As Jefferies Hikes Price Target

Glaukos Corporation stocks have been trading up by 6.55 percent following impactful glaucoma-treatment advancements boosting investor optimism.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading GKOS

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways Traders Need To Know

Jefferies lifted its GKOS price target from $190 to $210 and kept a Buy rating, highlighting confidence in Glaukos versus a pressured ophthalmology group.
A new “Could it be KC?” keratoconus awareness push taps Stephen Curry to share his own diagnosis story and steer patients to eye-care pros sooner.
The Stephen Curry campaign is slated to run into 2027, signaling a long game for GKOS in building the keratoconus treatment funnel.
The awareness effort backs Glaukos’ FDA-approved corneal cross-linking therapy and strengthens the company’s broader corneal disease franchise.

Live Update At 16:46:26 EDT: On Wednesday, October 07, 2026 Glaukos Corporation stock [NYSE: GKOS] is trending up by 6.55%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

GKOS has been grinding higher on the chart, and the numbers back up why traders are watching it closely. Over the past couple of weeks, Glaukos has climbed from the mid‑$150s to around $172, with the latest daily candle on 2026/10/07 showing a strong close near the top of the range at $172.18 after touching $174.48. That’s a clear sign of dip buying and resilient demand.

Intraday action shows GKOS holding bids all afternoon, trading mostly between $172 and $174 with only brief dips. That kind of tight, controlled tape says funds and steady hands are in there, not just quick scalpers. For momentum traders, GKOS is acting like a name where pullbacks are getting soaked up.

More Breaking News

Fundamentally, Glaukos is still a classic high‑growth, not‑yet‑profitable medtech story. Revenue over the last year sits near $507.4M, growing above 20% annually, but margins remain negative, with operating margin around -31%. Cash flow is improving: GKOS generated about $14.8M in operating cash in the latest quarter and posted positive free cash flow near $12.1M. A current ratio of 5.0 and low debt (total debt to equity only 0.15) give Glaukos a solid balance sheet cushion while it scales.

Why Traders Are Watching GKOS Momentum

The big spark for GKOS right now is the Street endorsement. Jefferies just raised its Glaukos price target from $190 to $210 and stuck with a Buy rating, even while the broader ophthalmology space feels pressure. When a major shop lifts targets in a weak group, it tells you they see GKOS as the outperformer. Traders respect that. It sets a psychological anchor above current levels and encourages dip buyers to stay aggressive.

On the tape, GKOS is trading like a stock that wants higher prices. The last session opened at $161 and ripped intraday to just under $174 before consolidating near $172. That’s a wide range with strong follow‑through, a pattern momentum traders hunt for. The 5‑minute chart shows a classic morning shakeout into the high $160s, then a controlled grind higher all day with closing prints near the highs. Weak hands got washed out early; stronger hands closed it.

News flow is also lining up with that momentum. Glaukos launched the “Could it be KC?” keratoconus awareness campaign with Stephen Curry sharing his own keratoconus story. That’s not just feel‑good marketing. For GKOS, it directly funnels attention toward its FDA‑approved corneal cross‑linking therapy and corneal franchise. More awareness usually means more diagnoses, which over time can mean more eligible patients and higher procedure volumes.

The Curry campaign is built as a multi‑year push with activities planned into 2027. That tells traders Glaukos is playing offense, not just defending share. While the immediate revenue impact is tough to model, the narrative is clear: GKOS is investing behind a key growth pillar, just as Wall Street raises its long‑term target.

Conclusion

Put it all together and GKOS sits in a sweet spot for active trading. The chart shows a strong uptrend off the $150s, with higher lows and powerful intraday reversals. The fundamentals show a high‑margin gross profile around 60.7%, fast top‑line growth near $185.6M in the latest quarter, and enough cash — roughly $286.2M in cash and short‑term investments as of 2026/06/30 — to keep funding R&D and commercial efforts. Yes, Glaukos still prints net losses, but negative EPS of -$0.31 last quarter is the price of building a medtech platform.

The Jefferies target hike to $210 gives traders a clear “north star” above the current GKOS price zone, while the Stephen Curry “Could it be KC?” campaign adds a powerful brand and demand story around keratoconus. GKOS now has both Street support and a consumer‑facing catalyst, a combination that often fuels sustained momentum when the market is paying attention.

For traders in the Tim Sykes community, this is the type of setup that demands preparation, not prediction. As Tim Sykes likes to remind people, “The market doesn’t owe you anything — it only rewards discipline, preparation, and the ability to cut losses quickly.” As Tim Bohen, lead trainer with StocksToTrade says, “If you’re still guessing at the end of your analysis, it’s probably not a trade worth taking.” GKOS is offering a clean narrative and a constructive chart. The job now is to map your levels, size smart, and let the price action confirm the story — not the other way around.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!